ClinicalTrials.gg
CompletedNCT01299454Updated Oct 20, 2015Results posted

A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects

A Phase 1 interventional study of OPC-34712 in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-20.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
20th of 28
45 · median 155
Started
2010
the only one that year
Phase 1
8 of 28
1 open now
Registered
4th of 28
by date
Lead sponsor
19 of 28
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 20th largest by enrollment, is the only one that started in 2010, is one of 8 in phase 1, and was the 4th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate how much of the investigational product gets into the blood stream and how long the body takes to get rid of it when given to subjects with a range of liver impairment compared to subjects with normal liver function.

Read the detailed description

This is a multi-center, open-label, parallel-arm study in 1 group of subjects with normal hepatic function and 3 groups of subjects with varying degrees of hepatic impairment (mild, moderate, and severe). Subjects will be confined to the clinic from Day -1 to Day 8. Subjects will be contacted via telephone 30 days (+ 2 days) after the last dose of study medication to assess any new or ongoing AEs and to record concomitant medications. All groups will receive a single oral 2-mg OPC-34712 dose on Day 1 with 240 mL room temperature still water. Subjects will be administered the OPC-34712 dose in the fasted state (at least 8 hours of fasting) and no food will be allowed for 4 hours postdose.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females of non- ≥ 18 years of age
  • Body weight within ± 30% of ideal body weight as defined in the 1983 Metropolitan Height and Weight Tables. Minimum body weight no less than 50 kg.
  • Able to provide written, .
  • Male and female subjects who are surgically sterile; female subjects who have been for at least 12 consecutive months; or male subjects who agree to remain abstinent or to practice double-barrier forms of and refrain from sperm donation from Screening through 90 days from the last dose of study medication.

Inclusion Criteria for Hepatically Impaired Subjects Only:

  • Hepatically impaired subjects with (CLcr) > 30 mL/min.
  • Subjects with hepatic impairment should have relatively stable hepatic function for the duration of the study, and otherwise be in generally good health.
  • A clinical diagnosis of hepatic cirrhosis based on and/or clinical criteria.
  • Class A (mild), B (moderate), or C (severe)
  • Hepatically impaired subjects may be taking medications, which in the opinion of the clinical investigator and sponsor, are believed to be therapeutic for the subjects.
  • Hepatically impaired subjects may have a history of or current hepatitis or be carriers of surface antigen (HBsAg) and/or antibodies (anti-HC).

Inclusion Criteria for Subjects with Normal Hepatic Function Only

  • Must be in good health as determined by medical history, physical examination, , serum/urine biochemistry, hematology, and serology tests.
  • Normal renal function as evidenced by CLcr that is within 20% of normal for the age, sex, and weight of the individual.

Exclusion criteria

Exclusion Criteria:

  • History of drug and/or alcohol abuse within 2 years prior to Screening.
  • History of acquired immunodeficiency syndrome or (HIV) antibodies.
  • History of any significant drug allergy or known or suspected .
  • A positive urine alcohol test and/or urine drug screen for substance of abuse at Screening or upon admission to the study center.
  • Subjects having taken an drug within 30 days preceding study entry.
  • Any history of significant bleeding or hemorrhagic tendencies. Subjects with a history of bleeding tendencies secondary to hepatic impairment will not be excluded.
  • A history of difficulty in donating blood.
  • The donation of blood or plasma within 30 days prior to dosing.
  • Consumption of alcohol and/or food and beverages containing methylxanthines, grapefruit, grapefruit juice, Seville oranges, or Seville orange juice within 72 hours prior to dosing.
  • Exposure to any substances known to stimulate hepatic microsomal enzymes within 30 days prior to Screening through the end of the study.
  • Subjects who have supine, sitting, or standing blood pressure, after resting for ≥ 3 minutes, higher than 140/90 mmHg or lower than 100/50 mmHg.
  • Subjects who have a supine pulse rate, after resting for ≥ 3 minutes, outside the range of 40 to 90 bpm.
  • Previous exposure to OPC-34712.
  • Subjects who are pregnant or breastfeeding.
  • Subjects with a interval ≥ 450 msec.
  • Subjects with PT greater than 2 times control. Subjects with hepatic impairment with prolonged PT will be excluded based on the PI's discretion.
  • Subjects with hepatic carcinoma or porto-hepatic shunts that have been surgically created or planted.
  • > 70 seconds.

Exclusion Criteria for Hepatically Impaired Subjects Only:

  • History of serious mental disorder including subjects who are pre-encephalopathic or encephalopathic as assessed by the score and/or the PI's judgment.
  • Major surgery of the digestive tract.

Exclusion Criteria for Subjects with Normal Hepatic Function Only:

  • abnormality in past medical history.
  • History of or current hepatitis, or carriers of and/or anti-HC.
  • Use of prescription, over-the-counter, herbal medication or vitamin supplements within 14 days prior to dosing and antibiotics within 30 days prior to dosing.
  • History of serious mental disorders.
  • Major surgery of the digestive tract (excluding appendectomy).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Active comparator
    Normal

    Drug: OPC-34712

  • Active comparator
    Mild

    Drug: OPC-34712

  • Active comparator
    Moderate

    Drug: OPC-34712

  • Active comparator
    Severe

    Drug: OPC-34712

Interventions

  • DrugBrexpiprazoleStudies of BrexpiprazoleBrexpiprazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All groups will receive a single oral 2-mg OPC-34712 dose on Day 1 with 240 mL room temperature still water. Subjects will be administered the OPC-34712 dose in the fasted state (at least 8 hours of fasting) and no food will be allowed for 4 hours postdose. Water will be restricted as part of the dosing procedure from 1 hour prior to dosing and 2 hours post-dose.

06

What researchers measure

Primary outcomes

  1. Unbound Brexpiprazole Area Under the Concentration Time Curve (AUC) Calculated to the Last Observable Concentration at Time t (AUCt,u)

    Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/Early termination (ET).

    Time frame: Day 1 to Day 8

  2. Unbound Brexpiprazole AUC Calculated From Time Zero to Infinity (AUC∞,u)

    Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. AUC (0 - ∞)= AUC from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: Day 1 to Day 8

  3. Unbound Maximum Plasma Concentration of Brexpiprazole (Cmax,u)

    Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Cmax,u is the highest measured unbound plasma concentration during the dosing interval.

    Time frame: Day 1 to Day 8

Secondary outcomes

  1. Area Under the Curve of Brexpiprazole Calculated to the Last Observable Concentration at Time t (AUCt)

    Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. AUCt= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t) The AUCt was estimated using the linear trapezoidal rule.

    Time frame: Day 1 to Day 8

  2. Area Under the Concentration Time Curve of Brexpiprazole From Time Zero to Infinity (AUC∞)

    Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. AUC (0 - ∞)= AUC from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). The AUC∞ was estimated using the linear trapezoidal rule

    Time frame: Day 1 to Day 8

  3. Maximum Plasma Concentration of Brexpiprazole (Cmax)

    Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Cmax is the highest measured concentration of the drug during the dosing interval. Actual blood sample times were used for PK calculations. Values for Cmax and tmax were determined directly from the observed data.

    Time frame: Day 1 to Day 8

  4. Time to Cmax of Brexiprazole (Tmax)

    Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Tmax is the time taken to reach highest measured concentration of the drug during the dosing interval. Actual blood sample times were used for PK calculations. Values for Cmax and tmax were determined directly from the observed data.

    Time frame: Day 1 to Day 8

  5. Apparent Clearance of Brexpiprazole From Plasma After Extravascular Administration (CL/F)

    The value of CL/F (brexpiprazole only) was determined as Dose/AUC∞. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Day 1 to Day 8

  6. Unbound Fraction of Brexpiprazole in Plasma (fu)

    Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET.

    Time frame: Day 1 to Day 8

  7. Apparent Unbound Clearance of Brexpiprazole From Plasma After Extravascular Administration (CLu/F)

    Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. The value of CLu/F (brexpiprazole only) was determined as dose normalized unbound area under the concentration-time curve from time zero to infinity (Dose/AUC∞,u).

    Time frame: Day 1 to Day 8

  8. Terminal-phase Elimination Half-life of Brexpiprazole (t1/2,z)

    Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. The t1/2,z was determined as (ln2)/λz. Terminal-phase elimination half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Day 1 to Day 8

  9. Renal Clearance (CLr) of Brexipiprazole

    Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of CLr was calculated as Ae,u/AUCt.

    Time frame: Day 1 to Day 8

  10. Cumulative Amount of Brexpiprazole Excreted Into the Urine (Ae,u)

    Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of Ae,u was calculated as the summation of urine concentration × urine volume from each collection interval

    Time frame: Day 1 to Day 8

  11. Fraction of Systemically Available Brexpiprazole Excreted Into the Urine (fe,u)

    Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose.. The value of fe,u was calculated as 100 × Ae,u/Dose.

    Time frame: Day 1 to Day 8

  12. AUCt for DM-3411 Metabolite

    Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. AUCt= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t) The AUCt was estimated using the linear trapezoidal rule.

    Time frame: Day 1 to Day 8

  13. AUC∞ for DM-3411 Metabolite

    Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. The AUC∞ were estimated using the linear trapezoidal rule.

    Time frame: Day 1 to Day 8

  14. Cmax for DM-3411 Metabolite

    Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Cmax is the highest measured concentration of the metabolite during the dosing interval.

    Time frame: Day 1 to Day 8

  15. Tmax for DM-3411 Metabolite

    Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Tmax is the time taken to reach highest measured concentration of the metabolite during the dosing interval.

    Time frame: Day 1 to Day 8

  16. t1/2,z for DM-3411 Metabolite

    Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. The t1/2,z was determined as (ln2)/λz.

    Time frame: Day 1 to Day 8

  17. Ae,u for DM-3411 Metabolite

    Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of Ae,u was calculated as the summation of urine concentration × urine volume from each collection interval.

    Time frame: Day 1 to Day 8

  18. fe,u for DM-3411 Metabolite

    Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of fe,u was calculated as 100 × Ae,u/Dose.

    Time frame: Day 1 to Day 8

  19. CLr for DM-3411 Metabolite

    Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of CLr was calculated as Ae,u/AUCt.

    Time frame: Day 1 to Day 8

  20. Number of Adverse Events (AEs) Reported

    AEs were captured for all participants from the time the ICF was signed until the end of the study

    Time frame: From the time the Informed Consent Form was signed, throughout the 8 day study up to 30 days after study drug administration.

  21. Number of Participants With Changes From Baseline in Vital Signs Parameters.

    Vital signs (including blood pressure, heart rate, temperature, and respiratory rate) were assessed at Screening, Day -1, Day 1 at predose (within 45 minutes prior to dosing), and 2, 4, 6, 8, 12, 24, 72, 120, and 168/ET hours postdose. Blood pressure and heart rate were taken with the subject in the supine (performed first), sitting, and standing

    Time frame: Day -1 to Day 8

  22. Number of Participants With Changes From Baseline in Electrocardiogram (ECG) Parameters.

    Electrocardiograms were performed at Screening, Day -1, and Day 1 at predose (in triplicate; within 45 minutes prior to dosing), and 2, 4, 6, 8, 12, 24, 72, 120, and 168/ET hours postdose. Standard 12-lead ECGs were performed after the subject was supine and at rest for ≥ 10 minutes prior to the ECG.

    Time frame: Day-1 to Day 8

  23. Number of Participants With Changes From Baseline in Serum Chemistry, Hematology and Urinalysis Parameters.

    Hematology, serum chemistry, and urinalysis, including prothrombin time, international normalized ratio, partial thromboplastin time, and activated partial thromboplastin time, were completed at Screening, Day -1, Day 3 (48 hours postdose), and Day 8 (168 hours postdose)/ET.

    Time frame: Day -1 to Day 8

  24. Incidence of Suicidality, Suicidal Behaviour or Suicidal Ideation as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)

    The Baseline version of the C-SSRS was administered at Screening. The Since Last Visit version of the C-SSRS was administered on Day 1 at predose and on Days 4 and 7.

    Time frame: Day 1, Day 4, Day 7

07

Results

Posted Sep 3, 2015

Participant flow

81 participants were screened; of these 45 participants were enrolled recruited at 3 study sites in the United States (US).

Participant flow — Overall Study
MilestoneMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentNormal Hepatic Function
Started88623
Completed88623
Not completed0000

Outcome measures

PrimaryUnbound Brexpiprazole Area Under the Concentration Time Curve (AUC) Calculated to the Last Observable Concentration at Time t (AUCt,u)

Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/Early termination (ET).

Time frame:
Day 1 to Day 8
Reported as:
Mean · nanograms.hours/mL (ng*h/mL)
Unbound Brexpiprazole Area Under the Concentration Time Curve (AUC) Calculated to the Last Observable Concentration at Time t (AUCt,u)
nanograms.hours/mL (ng*h/mL)Mild Hepatic ImpairmentNormal Hepatic Function Matched to Mild Hepatic FunctionModerate Hepatic ImpairmentNormal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic ImpairmentNormal Hepatic Function Matched to Severe Hepatic Function.
Unbound Brexpiprazole Area Under the Concentration Time Curve (AUC) Calculated to the Last Observable Concentration at Time t (AUCt,u)5.95 ± 2.584.87 ± 1.785.41 ± 1.374.28 ± 1.953.27 ± 0.933.63 ± 1.54
Statistical analysis
  • Mild Hepatic Impairment vs Normal Hepatic Function Matched to Mild Hepatic Function · Mixed effect analysis of variance · Geometric mean ratio: 1.166 · 90% CI 0.776 to 1.751Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
  • Moderate Hepatic Impairment vs Normal Hepatic Function Matched to Moderate Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 1.375 · 90% CI 0.915 to 2.066Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
  • Severe Hepatic Impairment vs Normal Hepatic Function Matched to Severe Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 0.929 · 90% CI 0.581 to 1.488Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
PrimaryUnbound Brexpiprazole AUC Calculated From Time Zero to Infinity (AUC∞,u)

Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. AUC (0 - ∞)= AUC from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame:
Day 1 to Day 8
Reported as:
Mean · ng*h/mL
Unbound Brexpiprazole AUC Calculated From Time Zero to Infinity (AUC∞,u)
ng*h/mLMild Hepatic ImpairmentNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic Impairment.Normal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic FunctionNormal Hepatic Function Matched to Severe Hepatic Function.
Unbound Brexpiprazole AUC Calculated From Time Zero to Infinity (AUC∞,u)8.59 ± 5.295.85 ± 3.118.50 ± 2.175.62 ± 3.133.49 ± 0.8483.36 ± 0.871
Statistical analysis
  • Mild Hepatic Impairment vs Normal Hepatic Function Matched to Mild Hepatic Function. · Mixed effect analysis of variance · Geometic mean ratio: 1.255 · 90% CI 0.702 to 2.244Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
  • Moderate Hepatic Impairment. vs Normal Hepatic Function Matched to Moderate Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 1.727 · 90% CI 0.977 to 3.052Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
  • Severe Hepatic Function vs Normal Hepatic Function Matched to Severe Hepatic Function. · Mixed effect analysis of variance · Geometic mean ratio: 1.041 · 90% CI 0.506 to 2.142Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
PrimaryUnbound Maximum Plasma Concentration of Brexpiprazole (Cmax,u)

Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Cmax,u is the highest measured unbound plasma concentration during the dosing interval.

Time frame:
Day 1 to Day 8
Reported as:
Mean · ng/mL
Unbound Maximum Plasma Concentration of Brexpiprazole (Cmax,u)
ng/mLMild Hepatic ImpairmentNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic ImpairmentNormal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic ImpairmentNormal Hepatic Function Matched to Severe Hepatic Function.
Unbound Maximum Plasma Concentration of Brexpiprazole (Cmax,u)0.104 ± 0.02590.114 ± 0.02700.0648 ± 0.01430.0779 ± 0.02240.0392 ± 0.01050.0760 ± 0.0258
Statistical analysis
  • Mild Hepatic Impairment vs Normal Hepatic Function Matched to Mild Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 0.904 · 90% CI 0.707 to 1.156Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
  • Moderate Hepatic Impairment vs Normal Hepatic Function Matched to Moderate Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 0.850 · 90% CI 0.665 to 1.087Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
  • Severe Hepatic Impairment vs Normal Hepatic Function Matched to Severe Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 0.531 · 90% CI 0.399 to 0.705Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
SecondaryArea Under the Curve of Brexpiprazole Calculated to the Last Observable Concentration at Time t (AUCt)

Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. AUCt= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t) The AUCt was estimated using the linear trapezoidal rule.

Time frame:
Day 1 to Day 8
Reported as:
Mean · ng*h/mL
Area Under the Curve of Brexpiprazole Calculated to the Last Observable Concentration at Time t (AUCt)
ng*h/mLMild Hepatic ImpairmentNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic ImpairmentNormal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic ImpairmentNormal Hepatic Function Matched to Severe Hepatic Function.
Area Under the Curve of Brexpiprazole Calculated to the Last Observable Concentration at Time t (AUCt)1271 ± 5691145 ± 5391213 ± 4051048 ± 422622 ± 163817 ± 306
Statistical analysis
  • Mild Hepatic Impairment vs Normal Hepatic Function Matched to Mild Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 1.103 · 90% CI 0.774 to 1.573Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
  • Moderate Hepatic Impairment vs Normal Hepatic Function Matched to Moderate Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 1.199 · 90% CI 0.841 to 1.710Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
  • Severe Hepatic Impairment vs Normal Hepatic Function Matched to Severe Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 0.790 · 90% CI 0.524 to 1.189Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
SecondaryArea Under the Concentration Time Curve of Brexpiprazole From Time Zero to Infinity (AUC∞)

Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. AUC (0 - ∞)= AUC from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). The AUC∞ was estimated using the linear trapezoidal rule

Time frame:
Day 1 to Day 8
Reported as:
Mean · ng*h/mL
Area Under the Concentration Time Curve of Brexpiprazole From Time Zero to Infinity (AUC∞)
ng*h/mLMild Hepatic ImpairmentNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic ImpairmentNormal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic ImpairmentNormal Hepatic Function Matched to Severe Hepatic Function.
Area Under the Concentration Time Curve of Brexpiprazole From Time Zero to Infinity (AUC∞)1827 ± 11031393 ± 8811960 ± 5791345 ± 697831 ± 234788 ± 230
Statistical analysis
  • Mild Hepatic Impairment vs Normal Hepatic Function Matched to Mild Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 1.241 · 90% CI 0.719 to 2.143Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
  • Moderate Hepatic Impairment vs Normal Hepatic Function Matched to Moderate Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 1.604 · 90% CI 0.942 to 2.732Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
  • Severe Hepatic Impairment vs Normal Hepatic Function Matched to Severe Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 1.077 · 90% CI 0.540 to 2.146Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
SecondaryMaximum Plasma Concentration of Brexpiprazole (Cmax)

Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Cmax is the highest measured concentration of the drug during the dosing interval. Actual blood sample times were used for PK calculations. Values for Cmax and tmax were determined directly from the observed data.

Time frame:
Day 1 to Day 8
Reported as:
Mean · ng/mL
Maximum Plasma Concentration of Brexpiprazole (Cmax)
ng/mLMild Hepatic ImpairmentNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic ImpairmentNormal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic ImpairmentNormal Hepatic Function Matched to Severe Hepatic Function.
Maximum Plasma Concentration of Brexpiprazole (Cmax)22.9 ± 7.6026.7 ± 9.0914.6 ± 4.6319.3 ± 4.987.65 ± 2.6917.7 ± 7.38
Statistical analysis
  • Mild Hepatic Impairment vs Normal Hepatic Function Matched to Mild Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 0.856 · 90% CI 0.691 to 1.059Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
  • Moderate Hepatic Impairment vs Normal Hepatic Function Matched to Moderate Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 0.742 · 90% CI 0.599 to 0.918Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
  • Severe Hepatic Impairment vs Normal Hepatic Function Matched to Severe Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 0.451 · 90% CI 0.352 to 0.577Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
SecondaryTime to Cmax of Brexiprazole (Tmax)

Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Tmax is the time taken to reach highest measured concentration of the drug during the dosing interval. Actual blood sample times were used for PK calculations. Values for Cmax and tmax were determined directly from the observed data.

Time frame:
Day 1 to Day 8
Reported as:
Median · h
Time to Cmax of Brexiprazole (Tmax)
hMild Hepatic ImpairmentNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic ImpairmentNormal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic FunctionNormal Hepatic Function Matched to Severe Hepatic Function.
Time to Cmax of Brexiprazole (Tmax)3.50 (1.00 to 5.00)3.50 (2.00 to 5.00)4.50 (3.00 to 24.0)4.50 (1.00 to 6.00)5.00 (4.00 to 24.0)5.00 (2.00 to 6.00)
SecondaryApparent Clearance of Brexpiprazole From Plasma After Extravascular Administration (CL/F)

The value of CL/F (brexpiprazole only) was determined as Dose/AUC∞. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Day 1 to Day 8
Reported as:
Mean · mL/h/kg
Apparent Clearance of Brexpiprazole From Plasma After Extravascular Administration (CL/F)
mL/h/kgMild Hepatic ImpairmentNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic ImpairmentNormal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic ImpairmentNormal Hepatic Function Matched to Severe Hepatic Function.
Apparent Clearance of Brexpiprazole From Plasma After Extravascular Administration (CL/F)24.5 ± 28.225.4 ± 12.313.8 ± 2.7226.0 ± 19.228.2 ± 6.7034.2 ± 16.3
SecondaryUnbound Fraction of Brexpiprazole in Plasma (fu)

Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET.

Time frame:
Day 1 to Day 8
Reported as:
Mean · % unbound drug in the urine
Unbound Fraction of Brexpiprazole in Plasma (fu)
% unbound drug in the urineMild Hepatic FunctionNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic FunctionNormal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic FunctionNormal Hepatic Function Matched to Severe Hepatic Function.
Unbound Fraction of Brexpiprazole in Plasma (fu)0.472 ± 0.08400.451 ± 0.1120.462 ± 0.07860.400 ± 0.04420.544 ± 0.1860.450 ± 0.0795
SecondaryApparent Unbound Clearance of Brexpiprazole From Plasma After Extravascular Administration (CLu/F)

Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. The value of CLu/F (brexpiprazole only) was determined as dose normalized unbound area under the concentration-time curve from time zero to infinity (Dose/AUC∞,u).

Time frame:
Day 1 to Day 8
Reported as:
Mean · mL/h/kg
Apparent Unbound Clearance of Brexpiprazole From Plasma After Extravascular Administration (CLu/F)
mL/h/kgMild Hepatic ImpairmentNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic FunctionNormal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic FunctionNormal Hepatic Function Matched to Severe Hepatic Function.
Apparent Unbound Clearance of Brexpiprazole From Plasma After Extravascular Administration (CLu/F)5674 ± 71655730 ± 29443115 ± 4946768 ± 58336598 ± 11827697 ± 2653
SecondaryTerminal-phase Elimination Half-life of Brexpiprazole (t1/2,z)

Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. The t1/2,z was determined as (ln2)/λz. Terminal-phase elimination half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Day 1 to Day 8
Reported as:
Mean · h
Terminal-phase Elimination Half-life of Brexpiprazole (t1/2,z)
hMild Hepatic FunctionNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic FunctionNormal Hepatic Function Matched to Moderate Hepatic Function.Sever Hepatic FunctionNormal Hepatic Function Matched to Severe Hepatic Function.
Terminal-phase Elimination Half-life of Brexpiprazole (t1/2,z)103 ± 51.164.7 ± 24.6116 ± 25.864.2 ± 26.281.1 ± 17.151.4 ± 8.21
SecondaryRenal Clearance (CLr) of Brexipiprazole

Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of CLr was calculated as Ae,u/AUCt.

Time frame:
Day 1 to Day 8
Reported as:
Mean · mL/h/kg
Renal Clearance (CLr) of Brexipiprazole
mL/h/kgMild Hepatic ImpairmentNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic ImpairmentNormal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic ImpairmentNormal Hepatic Function Matched to Severe Hepatic Function.
Renal Clearance (CLr) of Brexipiprazole0.0468 ± 0.03530.0263 ± 0.02440.0360 ± 0.02860.0422 ± 0.03830.0402 ± 0.08720.0193 ± 0.0203
SecondaryCumulative Amount of Brexpiprazole Excreted Into the Urine (Ae,u)

Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of Ae,u was calculated as the summation of urine concentration × urine volume from each collection interval

Time frame:
Day 1 to Day 8
Reported as:
Mean · ng
Cumulative Amount of Brexpiprazole Excreted Into the Urine (Ae,u)
ngMild Hepatic FunctionNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic FunctionNormal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic FunctionNormal Hepatic Function Matched to Severe Hepatic Function.
Cumulative Amount of Brexpiprazole Excreted Into the Urine (Ae,u)4511 ± 38081854 ± 15003522 ± 27403837 ± 33582090 ± 46991326 ± 1427
SecondaryFraction of Systemically Available Brexpiprazole Excreted Into the Urine (fe,u)

Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose.. The value of fe,u was calculated as 100 × Ae,u/Dose.

Time frame:
Day 1 to Day 8
Reported as:
Mean · % of drug in urine
Fraction of Systemically Available Brexpiprazole Excreted Into the Urine (fe,u)
% of drug in urineMild Hepatic ImpairmentNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic ImpairmentNormal Hepatic Function Matched to Moderate Hepatic FunctionSevere Hepatic ImpairmentNormal Hepatic Function Matched to Severe Hepatic Function.
Fraction of Systemically Available Brexpiprazole Excreted Into the Urine (fe,u)0.226 ± 0.1900.0927 ± 0.07500.176 ± 0.1370.192 ± 0.1680.104 ± 0.2350.0663 ± 0.0713
SecondaryAUCt for DM-3411 Metabolite

Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. AUCt= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t) The AUCt was estimated using the linear trapezoidal rule.

Time frame:
Day 1 to Day 8
Reported as:
Mean · ng*h/mL
AUCt for DM-3411 Metabolite
ng*h/mLMild Hepatic ImpairmentNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic ImpairmentNormal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic ImpairmentNormal Hepatic Function Matched to Severe Hepatic Function.
AUCt for DM-3411 Metabolite380 ± 195683 ± 246284 ± 164486 ± 263151 ± 51.4479 ± 226
Statistical analysis
  • Mild Hepatic Impairment vs Normal Hepatic Function Matched to Mild Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 0.509 · 90% CI 0.346 to 0.748
  • Moderate Hepatic Impairment vs Normal Hepatic Function Matched to Moderate Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 0.586 · 90% CI 0.399 to 0.861Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
  • Severe Hepatic Impairment vs Normal Hepatic Function Matched to Severe Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 0.334 · 90% CI 0.214 to 0.521Due to the nature of the normal-theory CIs, this approach is equivalent to carrying out two 1-sided tests of hypothesis at the 5% level of significance.
SecondaryAUC∞ for DM-3411 Metabolite

Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. The AUC∞ were estimated using the linear trapezoidal rule.

Time frame:
Day 1 to Day 8
Reported as:
Mean · ng*h/mL
AUC∞ for DM-3411 Metabolite
ng*h/mLMild Hepatic ImpairmentNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic ImpairmentNormal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic ImpairmentNormal Hepatic Function Matched to Severe Hepatic Function.
AUC∞ for DM-3411 Metabolite489 ± 210692 ± 259382 ± 262530 ± 211187 ± 67.2329 ± 167
Statistical analysis
  • Mild Hepatic Impairment vs Normal Hepatic Function Matched to Mild Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 0.716 · 90% CI 0.445 to 1.153
  • Moderate Hepatic Impairment vs Normal Hepatic Function Matched to Moderate Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 0.594 · 90% CI 0.378 to 0.934
  • Severe Hepatic Impairment vs Normal Hepatic Function Matched to Severe Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 0.561 · 90% CI 0.308 to 1.022
SecondaryCmax for DM-3411 Metabolite

Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Cmax is the highest measured concentration of the metabolite during the dosing interval.

Time frame:
Day 1 to Day 8
Reported as:
Mean · ng/mL
Cmax for DM-3411 Metabolite
ng/mLMild Hepatic ImpairmentNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic ImpairmentNormal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic ImpairmentNormal Hepatic Function Matched to Severe Hepatic Function.
Cmax for DM-3411 Metabolite6.49 ± 5.1310.5 ± 4.263.19 ± 1.567.25 ± 4.832.15 ± 0.8807.13 ± 3.73
Statistical analysis
  • Mild Hepatic Impairment vs Normal Hepatic Function Matched to Mild Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 0.558 · 90% CI 0.368 to 0.845
  • Moderate Hepatic Impairment vs Normal Hepatic Function Matched to Moderate Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 0.516 · 90% CI 0.341 to 0.781
  • Severe Hepatic Impairment vs Normal Hepatic Function Matched to Severe Hepatic Function. · Mixed effect analysis of variance · Geometric mean ratio: 0.314 · 90% CI 0.195 to 0.507
SecondaryTmax for DM-3411 Metabolite

Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Tmax is the time taken to reach highest measured concentration of the metabolite during the dosing interval.

Time frame:
Day 1 to Day 8
Reported as:
Median · h
Tmax for DM-3411 Metabolite
hMild Hepatic FunctionNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic FunctionNormal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic FunctionNormal Hepatic Function Matched to Severe Hepatic Function.
Tmax for DM-3411 Metabolite5.00 (2.00 to 24.0)6.00 (5.00 to 24.0)5.00 (2.00 to 24.0)7.00 (2.00 to 24.0)4.5 (3.00 to 24.0)6.00 (5.00 to 16.0)
Secondaryt1/2,z for DM-3411 Metabolite

Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. The t1/2,z was determined as (ln2)/λz.

Time frame:
Day 1 to Day 8
Reported as:
Mean · h
t1/2,z for DM-3411 Metabolite
hMild Hepatic ImpairmentNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic ImpairmentNormal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic ImpairmentNormal Hepatic Function Matched to Severe Hepatic Function.
t1/2,z for DM-3411 Metabolite78.8 ± 37.659.7 ± 15.787.2 ± 45.762.0 ± 26.484.6 ± 12.056.1 ± 8.25
SecondaryAe,u for DM-3411 Metabolite

Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of Ae,u was calculated as the summation of urine concentration × urine volume from each collection interval.

Time frame:
Day 1 to Day 8
Reported as:
Mean · ng
Ae,u for DM-3411 Metabolite
ngMild Hepatic FunctionNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic FunctionNormal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic FunctionNormal Hepatic Function Matched to Severe Hepatic Function.
Ae,u for DM-3411 Metabolite67086 ± 2527681148 ± 2318868413 ± 1699371353 ± 4163048190 ± 1475683604 ± 34907
Secondaryfe,u for DM-3411 Metabolite

Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of fe,u was calculated as 100 × Ae,u/Dose.

Time frame:
Day 1 to Day 8
Reported as:
Mean · % metabolite excreted in urine
fe,u for DM-3411 Metabolite
% metabolite excreted in urineMild Hepatic FunctionNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic FunctionNormal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic FunctionNormal Hepatic Function Matched to Severe Hepatic Function.
fe,u for DM-3411 Metabolite3.23 ± 1.223.91 ± 1.123.30 ± 0.8193.44 ± 2.012.32 ± 0.7124.03 ± 1.68
SecondaryCLr for DM-3411 Metabolite

Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of CLr was calculated as Ae,u/AUCt.

Time frame:
Day 1 to Day 8
Reported as:
Mean · mL/h/kg
CLr for DM-3411 Metabolite
mL/h/kgMild Hepatic ImpairmentNormal Hepatic Function Matched to Mild Hepatic Function.Moderate Hepatic ImpairmentNormal Hepatic Function Matched to Moderate Hepatic Function.Severe Hepatic ImpairmentNormal Hepatic Function Matched to Severe Hepatic Function.
CLr for DM-3411 Metabolite2.67 ± 1.311.83 ± 0.8283.96 ± 2.321.90 ± 0.5684.08 ± 1.682.33 ± 1.01
SecondaryNumber of Adverse Events (AEs) Reported

AEs were captured for all participants from the time the ICF was signed until the end of the study

Time frame:
From the time the Informed Consent Form was signed, throughout the 8 day study up to 30 days after study drug administration.
Reported as:
Number · Events
Number of Adverse Events (AEs) Reported
EventsMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentNormal Hepatic Function
Adverse events3518
Treatment emergent adverse events3516
Serious adverse events0000
SecondaryNumber of Participants With Changes From Baseline in Vital Signs Parameters.

Vital signs (including blood pressure, heart rate, temperature, and respiratory rate) were assessed at Screening, Day -1, Day 1 at predose (within 45 minutes prior to dosing), and 2, 4, 6, 8, 12, 24, 72, 120, and 168/ET hours postdose. Blood pressure and heart rate were taken with the subject in the supine (performed first), sitting, and standing

Time frame:
Day -1 to Day 8
Reported as:
Number · Participants
Number of Participants With Changes From Baseline in Vital Signs Parameters.
ParticipantsMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentNormal Hepatic Function
Number of Participants With Changes From Baseline in Vital Signs Parameters.0000
SecondaryNumber of Participants With Changes From Baseline in Electrocardiogram (ECG) Parameters.

Electrocardiograms were performed at Screening, Day -1, and Day 1 at predose (in triplicate; within 45 minutes prior to dosing), and 2, 4, 6, 8, 12, 24, 72, 120, and 168/ET hours postdose. Standard 12-lead ECGs were performed after the subject was supine and at rest for ≥ 10 minutes prior to the ECG.

Time frame:
Day-1 to Day 8
Reported as:
Number · Participants
Number of Participants With Changes From Baseline in Electrocardiogram (ECG) Parameters.
ParticipantsMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentNormal Hepatic Function
Number of Participants With Changes From Baseline in Electrocardiogram (ECG) Parameters.0000
SecondaryNumber of Participants With Changes From Baseline in Serum Chemistry, Hematology and Urinalysis Parameters.

Hematology, serum chemistry, and urinalysis, including prothrombin time, international normalized ratio, partial thromboplastin time, and activated partial thromboplastin time, were completed at Screening, Day -1, Day 3 (48 hours postdose), and Day 8 (168 hours postdose)/ET.

Time frame:
Day -1 to Day 8
Reported as:
Number · Participant
Number of Participants With Changes From Baseline in Serum Chemistry, Hematology and Urinalysis Parameters.
ParticipantMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentNormal Hepatic Function
Number of Participants With Changes From Baseline in Serum Chemistry, Hematology and Urinalysis Parameters.0000
SecondaryIncidence of Suicidality, Suicidal Behaviour or Suicidal Ideation as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)

The Baseline version of the C-SSRS was administered at Screening. The Since Last Visit version of the C-SSRS was administered on Day 1 at predose and on Days 4 and 7.

Time frame:
Day 1, Day 4, Day 7
Reported as:
Number · Participants
Incidence of Suicidality, Suicidal Behaviour or Suicidal Ideation as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)
ParticipantsMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentNormal Hepatic Function
Incidence of Suicidality, Suicidal Behaviour or Suicidal Ideation as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)0000

Adverse events

Collected over Adverse events were recorded from the time the Informed Consent Form was signed, throughout the 8 day study up to 30 days after study drug administration.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mild Hepatic Impairment—0/8 (0%)3/8 (37.5%)
Moderate Hepatic Impairment—0/8 (0%)3/8 (37.5%)
Severe Hepatic Impairment—0/6 (0%)1/6 (16.7%)
Normal Hepatic Function—0/23 (0%)6/23 (26.1%)
Most frequent other events
Most frequent other events
EventMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentNormal Hepatic Function
HeadacheNervous system disorders1/81/81/64/23
DiarrhoeaGastrointestinal disorders0/81/80/60/23
FatigueGeneral disorders1/81/80/60/23
DizzinessNervous system disorders1/80/80/60/23
SomnolenceNervous system disorders0/81/80/61/23
CoughRespiratory, thoracic and mediastinal disorders0/81/80/60/23
Musculoskeletal painMusculoskeletal and connective tissue disorders0/80/80/61/23

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Mild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentNormal Hepatic FunctionTotal
Mean59.5 ± 7.357.8 ± 3.851.2 ± 4.456.2 ± 5.256.4 ± 5.7
Sex: Female, Male
Sex: Female, Male(Participants)Mild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentNormal Hepatic FunctionTotal
Female320510
Male5661835
08

Study locations

3 sites
  • Study Site
    Miami, Florida 33014, United States
  • Study Site
    Minneapolis, Minnesota 55404, United States
  • Study Site
    San Antonio, Texas 78212, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Jun 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 4 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2011
First posted
Feb 18, 2011
Start
Dec 2010
Primary completionActual
Jun 2011
CompletionActual
Jul 2011
Results first posted
Sep 3, 2015
Last update
Oct 20, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01299454
Responsible party
Sponsor
First posted
Feb 18, 2011
Start date
Dec 2010
Primary completion
Jun 2011
Completion
Jul 2011
Results posted
Sep 3, 2015
Last update
Oct 20, 2015
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion